Literature DB >> 9186818

Twenty-four hour melatonin pattern in acromegaly: effect of acute octreotide administration.

A A Sinisi1, D Pasquali, A D'Apuzzo, D Esposito, T Venditto, T Criscuolo, A De Bellis, A Bellastella.   

Abstract

We investigated the melatonin (MT) circadian rhythm before and after somatostatin (octreotide) acute administration in ten subjects (4 M, 6 F. 23-52 yr old) with active acromegaly due to pituitary microadenoma. Blood samples were drawn every 2 hours over a 48-h span; after 24-h basal blood collection, octreotide (Sandostatin, Sandoz) 100 micrograms sc/8 h was administered. As control, 7 healthy adult subjects (3M, 4F; 26-50 yr old) were studied in basal condition over a 24-h span. Plasma MT and GH levels were measured by RIA in each sample, IGF-1 levels were measured by immunoradiometric assay in basal and after octreotide morning samples. The comparisons were made by Mann-U-Withney and Wilcoxon test as appropriate; the existence of a MT circadian rhythm was validated by cosinor analysis; GH and MT values were correlated by Pearson's correlation coefficient. All of 7 control subjects and 2 of 10 acromegalics had significant 24-h MT rhythm. The area under curve (AUC), mesor and amplitude of the MT rhythms in acromegalics were significantly lower than in the controls (p < 0.001, 0.002 and 0.0006, respectively), with an earlier acrophase (median value: 22:14 vs 02:08 h of controls). Basal plasma IGF-1 levels and circadian GH concentrations were significantly increased in acromegalics in comparison with the control group. Octreotide administration significantly reduced GH, restoring a circadian MT rhythm in 5 of 10 acromegalics, with MT mean mesor and AUC not different from controls. Mean amplitude still remained lower than controls (p < 0.0006), with an earlier acrophase (median 00:01 h). No significant correlation was found between individual GH and MT levels. Our data indicate a reduction of MT circadian secretion in acromegaly, due especially to a blunted nocturnal increase with earlier MT peak; moreover, acute octreotide administration increase MT levels without modifying amplitude and phase of night-time secretion significantly. These findings suggest a negative interrelationship between GH and MT secretions or a facilitatory influence of somatostatin on daytime MT release only. This partial recovery of pineal secretion after octreotide in acromegalics could be a clinically significant contribution to improve their quality of life, considering that MT is involved in the regulation of several important functions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186818     DOI: 10.1007/BF03346890

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

Review 1.  Plasma melatonin as a measure of the human clock.

Authors:  N E Rosenthal
Journal:  J Clin Endocrinol Metab       Date:  1991-08       Impact factor: 5.958

2.  Blindness impairs plasma growth hormone response to L-dopa but not to arginine.

Authors:  A Bellastella; F Parlato; A A Sinisi
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

3.  Growth hormone regulation by melatonin and serotonin.

Authors:  G A Smythe; L Lazarus
Journal:  Nature       Date:  1973-07-27       Impact factor: 49.962

Review 4.  Role of melatonin in health and disease.

Authors:  S M Webb; M Puig-Domingo
Journal:  Clin Endocrinol (Oxf)       Date:  1995-03       Impact factor: 3.478

Review 5.  Acromegaly and neoplasia.

Authors:  B A Bengtsson
Journal:  J Pediatr Endocrinol       Date:  1993 Jan-Mar

6.  Blindness influences the growth of institutionalized prepubertal subjects.

Authors:  A Bellastella; A A Sinisi; C Raiola; L Perrone; S Iorio; F Parlato; A Mazzuca; M Faggiano
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

7.  Different types of melatonin circadian secretory rhythms in some blind subjects.

Authors:  A J Lewy; D A Newsome
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

8.  Melatonin and the pituitary-thyroid axis status in blind adults: a possible resetting after puberty.

Authors:  A Bellastella; A A Sinisi; T Criscuolo; A De Bellis; C Carella; S Iorio; A M Sinisi; F Parlato; T Venditto; G Pisano
Journal:  Clin Endocrinol (Oxf)       Date:  1995-12       Impact factor: 3.478

9.  Suppression of human growth hormone secretion by melatonin and cyproheptadine.

Authors:  G A Smythe; L Lazarus
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

10.  Normal plasma insulin-like growth factor I levels and impaired final stature in adult blind subjects.

Authors:  A Bellastella; T Criscuolo; S Iorio; F Parlato; A A Sinisi; A M Sinisi; D Pasquali; G Pisano
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

View more
  2 in total

1.  A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers.

Authors:  E S Schernhammer; A Giobbie-Hurder; K Gantman; J Savoie; R Scheib; L M Parker; W Y Chen
Journal:  Cancer Causes Control       Date:  2012-02-28       Impact factor: 2.506

2.  The role of somatostatin (octreotide) in the regulation of melatonin secretion in healthy volunteers and in patients with primary hypothyroidism.

Authors:  J Wikner; L Wetterberg; S Röjdmark
Journal:  J Endocrinol Invest       Date:  1999 Jul-Aug       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.